Sulfapyridine

As of Nov 14, 2026, NDA 159 (Sulfapyridine), held by Lilly, was first approved by FDA on Mar 9, 1939, with 2 approved supplements and 0 published complete response letters.

First approved: Mar 9, 1939
Supplements approved: 2
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 3 submissions below

Date	Submission	Status	Documents
Mar 9, 1939	Original application	Approved	None posted

Products

1 strengths and forms

Product	Active ingredient	Marketing
Sulfapyridine500MG · tablet;oral	Sulfapyridine	Discontinued

All 3 submissions, including labeling and manufacturing supplements


Dec 9, 1986	Supplement 3Labeling	Approved	None posted
May 28, 1986	Supplement 4Labeling	Approved	None posted
Mar 9, 1939	Original application	Approved	None posted

Identifiers

Application: NDA 159
Drugs@FDA: Overview at FDA
Company: Lilly

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters